Original release date: October 22, 2020
Access to this course expires on: April 22, 2021 at 11:59 PM Pacific Time
Neuroendocrine differentiation in tumors of the prostate or in the setting of prostate cancer is rare. A survey of these lesions is presented, including usual prostate cancer with focal neuroendocrine marker-positive cells, Paneth cell-like change, prostatic ‘carcinoid’, high-grade neuroendocrine carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating neuroendocrine tumors involving the prostate from secondary involvement are highlighted.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Samson W. Fine, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
This item is expired.